CYRUS POONAWALLA

Cyrus Poonawalla was born in 1941 in Pune, India, to a family that bred racehorses. The Poonawalla Stud Farm was one of India's most successful thoroughbred breeding operations.

Cyrus was expected to continue the family horse business.

Instead, he saw an opportunity in healthcare. In 1966, he founded the Serum Institute of India (SII) with a simple thesis: India and the developing world needed affordable vaccines.

Western pharmaceutical companies priced vaccines for rich-country margins. Poonawalla would make the same vaccines at a fraction of the cost.

He started by manufacturing anti-tetanus and anti-snake venom serums. Gradually, SII expanded into childhood vaccines, DPT, measles, hepatitis B, and others, using the horses from the family farm to produce equine serums.

By the 2000s, SII was the world's largest vaccine manufacturer by number of doses produced. Over 65% of the world's children received at least one SII vaccine.

The company's products were used in over 170 countries.

When COVID hit in 2020, SII became the primary manufacturer of the Oxford-AstraZeneca vaccine, branded as Covishield. Cyrus's son Adar Poonawalla, who had taken over as CEO, negotiated the manufacturing deal and ramped production to over 100 million doses per month.

India's vaccination campaign, and much of the developing world's, depended on SII.

Covishield was priced at around $3 per dose for the Indian government, compared to $20-40 for mRNA vaccines. The low price was both a humanitarian achievement and a business strategy.

Volume over margin, the same approach that made SII dominant in the first place.

Serum Institute of India is the core. The world's largest vaccine manufacturer by doses, producing over 1.5 billion doses annually.

Products include vaccines for polio, measles, flu, COVID, meningitis, pneumonia, and more. Revenue exceeds $2 billion annually.

SII also manufactures biosimilars and is expanding into cancer treatments and gene therapy.

Poonawalla Fincorp is the family's financial services arm, offering loans and financial products in India.

The family still operates the Poonawalla Stud Farm, one of India's premier thoroughbred breeding operations. The contrast between horse breeding and vaccine manufacturing is genuinely delightful.

Build one thing and be the best in the world at it. Poonawalla never diversified away from vaccines.

He didn't chase tech, real estate, or media. He just kept making vaccines cheaper and in larger volumes.

Volume over margin. SII's vaccines are priced for the developing world, not for Western pharmaceutical margins.

But at 1.5 billion doses per year, even thin margins produce enormous profits.

Reinvest relentlessly. SII plows profits back into manufacturing capacity, R&D, and new vaccine development.

The company has never paid a significant dividend.

Becoming the world's largest vaccine manufacturer. By focusing relentlessly on volume and affordability, SII supplies vaccines to over 170 countries.

The company vaccinates roughly 65% of the world's children.

The COVID response was the crowning achievement. Manufacturing over 1.5 billion doses of Covishield, supplying India's entire vaccination campaign and dozens of developing countries through COVAX.

While Western pharmaceutical companies were criticized for hoarding doses, SII was shipping to countries that couldn't afford mRNA vaccines.

SII was slow to develop its own vaccines rather than manufacturing others' formulations. For decades, the company relied on licensing deals, making other companies' vaccines at lower cost.

This limited SII's IP ownership and brand recognition in Western markets.

During COVID, the export ban imposed by the Indian government in early 2021 damaged SII's international reputation. Countries that had pre-ordered Covishield couldn't get deliveries because India needed the doses domestically.

While this was a government decision, SII took reputational damage.

There were also quality concerns raised about some SII products over the years, though these have generally been resolved.

Affordable healthcare is the best business model. When you make something essential affordable, the entire developing world becomes your market.

That's 6 billion potential customers.

Scale solves everything. At 1.5 billion doses per year, SII's manufacturing costs per dose are the lowest in the world.

No competitor can match their unit economics.

Stay private, stay independent. SII is privately held by the Poonawalla family.

No IPO, no outside investors, no quarterly earnings pressure. This lets them invest in decade-long R&D projects and price vaccines for affordability rather than shareholder returns.

Cyrus married Villoo Poonawalla, who was deeply involved in the business and philanthropic activities. She passed away in 2010.

His son Adar Poonawalla is now CEO of SII and has become one of the most prominent young business leaders in India. Adar handled the COVID vaccine negotiations and manufacturing ramp-up.

He's been praised for his operational execution during the pandemic.

The Poonawalla family is Parsi, a small but historically influential minority community in India known for business and philanthropy. Other famous Parsi families include the Tatas and the Godrej family.

Poonawalla studied at Brihan Maharashtra College of Commerce in Pune. He did not attend an elite Western university, unlike many Indian billionaires.

His education was practical and local, reflecting the self-made nature of his business.